A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Summary

This study, ELU- FRα-1, was focused on adult subjects who have advanced, recurrent or refractory folate receptor alpha (FRα) overexpressing tumors considered to be topoisomerase 1 inhibitor-sensitive based on scientific literature, and, in the opinion of the Investigator, have no other meaningful life-prolonging therapy options available.

Timeline

Start

2021-09-13

Primary completion

2024-06-07

Completion

2024-06-07

Outcome

Outcome not reported

Stopped (Business): “Lack of Funding - no safety issue with Drug; Company Permanently Closed”

Drugs

Indications